AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mdZjpwy
via IFTTT

Read More

Imported dialysis solution fails endotoxin test in Himachal; lab flags nine regulatory violations

A Himachal Pradesh government drug laboratory has declared two batches of an imported peritoneal dialysis solution “Not of Standard Quality” after they failed bacterial endotoxin tests. The report also flagged nine regulatory violations, including use of non-Indian pharmacopoeial standards, labelling deficiencies, missing safety warnings and inadequate importer details.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fbDLdI7
via IFTTT

Read More

Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

Alembic Pharmaceuticals has reported that its Vadodara facility passed the recent inspection by the United States Food and Drug Administration with flying colors. Conducted from August 31 to September 10, 2026, the inspection resulted in zero observations, leading to a clean report from the USFDA and highlighting the facility's commitment to excellence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6w7jzn
via IFTTT

Read More

India crosses 80 lakh HPV vaccinations in nationwide cervical cancer prevention drive

India has now administered over 80 lakh HPV vaccinations to girls. This significant milestone strengthens preventive healthcare and protection against HPV infection. The nationwide campaign, launched in February, targets fourteen-year-old girls for free vaccination. The Gardasil-4 vaccine is available at government health facilities across the country. Parental consent is mandatory for this voluntary immunization program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FGjfMd7
via IFTTT

Read More

Marengo Asia Hospitals raises Rs 400 crore from LeapFrog Investments

Marengo Asia Hospitals has secured Rs. 400 crore funding from LeapFrog Investments. This capital will fuel expansion into tier one and two Indian cities. The company plans to double its hospital bed capacity to 4,000 beds. Marengo Asia Hospitals aims to consolidate its leadership and enter new geographies. This investment reinforces LeapFrog's commitment to healthcare platforms across Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HnosAqO
via IFTTT

Read More

iKure bags USD 1.8 Million from global investors to expand primary healthcare in India

iKure Techsoft has successfully raised USD 1.8 million in Pre-Series A funding. This infusion of capital is set to bolster its frontline healthcare workforce and enhance infrastructure, while also advancing its digital health platform through AI integration. iKure aims to provide ongoing care to patients, ensuring access to vital healthcare services for underserved communities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9XYpLUM
via IFTTT

Read More

Regional healthcare hubs emerge as new investment hotspots

Investment is shifting to regional hospital hubs like Jaipur and Vadodara. These markets offer growth opportunities and lower operating costs for investors. Health insurance penetration is also increasing significantly in these areas. Single-specialty segments like IVF and mother-child care are driving deal activity. Regional hospital brands are expected to scale through clusters and strengthen networks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Dr5QALi
via IFTTT

Read More